Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

• मुख्य लेखकों: Juan Espinosa-Pereiro (लेखक), Samiksha Ghimire (लेखक), Marieke G. G. Sturkenboom (लेखक), Jan-Willem C. Alffenaar (लेखक), Margarida Tavares (लेखक), Sarita Aguirre (लेखक), Arturo Battaglia (लेखक), Gladys Molinas (लेखक), Teresa Tórtola (लेखक), Onno W. Akkerman (लेखक), Adrian Sanchez-Montalva (लेखक), Cecile Magis-Escurra (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2022-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those per...